MedTrace Logo

New Retinoid Agent Combined With Arsenic Trioxide for Untreated Acute Promyelocytic Leukemia

NCT00670150 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2015-10-27

No results posted yet for this study

Summary

The safety and efficacy of combining NRX 195183 with arsenic trioxide in treating untreated APL will be assessed.

Conditions

  • Acute Promyelocytic Leukemia

Interventions

DRUG

NRX 195183 (retinoid analogue)

30mg/m2 PO daily x 3mo.in Induction, then daily with consolidation

DRUG

Arsenic Trioxide

0.15mg/kg/day over 2hrs VI on day 1-5 x 4 weeks. 2 weeks rest then repeat x 3 more cycles.

Sponsors & Collaborators

  • Sponsor Name Pending

    collaborator INDUSTRY

  • University of Southern California

    lead OTHER

Principal Investigators

  • Dan Douer, MD · University of Southern California

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-05-31
Primary Completion
2010-08-31
Completion
2010-08-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00670150 on ClinicalTrials.gov